Your Medical AI Development PartnerProviding services in data preparation, AI development, and regulatory strategy
Who We Are
We are a team of research and development professionals experienced in applying AI to medical image analysis, bioinformatics, and natural language processing applications. Our AI R&D lab is located in Seattle, WA, and we work with clients worldwide.
Since 2016, we have been applying our AI expertise to some of the most challenging problems in healthcare. Many of our scientists worked together for over ten years before starting the company, developing advanced technologies for leading companies including GE and Qualcomm.
We value the strong relationships we have formed with our clinical collaboration partners around the world, including medical device manufacturers and a medical imaging post-processing center. We work closely with our partners to create scalable and compliant medical solutions that are owned by our clients.
These capabilities deliver clients a one-stop solution for developing advanced medical AI applications. We offer clients in the healthcare industry a productive R&D team capable of accelerating progress in medical AI to benefit patients and providers worldwide.
AI Application Development
We work with your team to develop customized solutions that fit your technical environment and patient care priorities.
Innovation begins in multidisciplinary collaborations between our machine learning scientists and clinical experts.
We have experience helping medical device manufacturers pursue regulatory clearance for their software medical devices.
The new coronavirus (COVID-19) outbreak hit close to home for our team at CuraCloud. We provide AI services to collaboration partners in China supporting over 100 hospitals, two of which are located in Wuhan, Hubei Province where the virus first appeared. It does not seem so far away.
According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States for both men and women.
In April 2019, the U.S. Food and Drug Administration published a discussion paper on a Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD).
Let's start something new together.